SASH1 and prostate cancer: In deed, Haj-Ahmad et al. also found that miR-1238 was over-expressed in 38% of the initial prostate cancer samples, and suspected that miR-1238 may target SASH1 (SAM & SH3 domain containing protein 1) [26] which was down-regulated in breast cancer [28].